WAILEA, Hawaii — There is “intense research” aimed at developing more effective, safer and more durable treatments for diabetic macular edema, Michael S. Ip, MD, said in a presentation at Hawaiian Eye 2021.
“One new approach is brolucizumab, which has a very high molar dose,” Ip said.
The KITE and KESTREL registration trials for Beovu (brolucizumab, Novartis) 6 mg met the phase 3 endpoints of non-inferiority vs. aflibercept 2 mg at 1 year in patients with DME.
Brolucizumab is the smallest known active unit of an antibody that allows for concentrated molar dosing, Ip